The British financial conglomerate Lloyds Banking Group (NYSE:LYG) is now looking to hire a cryptocurrency expert.
What Happened: According to a job description posted on a recruiting platform BYP, the banking giant is looking to hire a Digital Currency and Innovation Senior Manager.
While Lloyds Banking Group does not provide details regarding its crypto-related projects, it notes that it is in “the middle of a £3bn investment” with a “Software Engineering led approach.”
The bank admits that “the outlook for digital assets has shifted markedly” due to multiple factors having converged to “make them ready for the possibility of wider adoption.”
The candidate is expected to be “a team player with influential partnering skills and a background in payments services.”
Read also: Walmart Is Hiring A Digital Currency And Cryptocurrency Product Lead
The future executive is also required to have experience and knowledge of crypto and an understanding of the IT and payments spaces.
Lloyds Banking Group's Digital Currency & Innovation, Senior Manager, would be tasked — among other things — with leading the bank's fintech partnerships and developing “payments use cases and initiate business or investments orientated around the use of digital currencies.”
Hot Financial Stocks To Own For 2023: Agenus Inc.(AGEN)
Agenus Inc., a biotechnology company, engages in developing and commercializing technologies to treat cancers and infectious diseases. It offers Oncophage vaccine for the treatment of adjuvant renal cell carcinoma. The company?s products under development include Prophage series of cancer vaccines, which has been tested in Phase III clinical trials for the treatment of renal cell carcinoma (RCC) and metastatic melanoma, as well as has been tested in Phase I and Phase II clinical trials in various indications; and under Phase II clinical trials in glioma, a type of brain cancer, and adjuvant renal cell carcinoma. The Prophage series of cancer vaccines include R-series candidates in RCC, M-series candidates in melanoma, and G-series candidates in glioma. Its product candidate portfolio includes QS-21 Stimulon adjuvant, which is in Phase III clinical trials for the treatment of non-small cell lung cancer, melanoma, malaria, and shingles, as well as in for the treatment of va rious infectious diseases and Alzheimer?s disease; and HerpV that completed Phase 1 clinical trial for the treatment of genital herpes. The company was formerly known as Antigenics Inc. and changed its name Agenus Inc. in January 2011 to reflect its existing product pipeline. Agenus Inc. was founded in 1994 and is headquartered in Lexington, Massachusetts.
- [By Motley Fool Transcribers]
Agenus Inc (NASDAQ:AGEN)Q4 2018 Earnings Conference CallMarch 14, 2019, 8:30 a.m. ET
Prepared Remarks Questions and Answers Call Participants
- [By Cory Renauer]
These three start-ups have gotten close more than once, but they still don’t have any products to sell. What they have created, though, is a trail of disappointed investors who have watched at least $1 billion go up in flames.
Company (Symbol) Market Capitalization Year of Incorporation Accumulated Deficit, Sept. 30, 2018 Focus
Novavax (NASDAQ:NVAX) $269 million 1987 $1.25 billion Vaccines
Geron (NASDAQ:GERN) $285 million 1990 $1.00 billion Oncology
Agenus (NASDAQ:AGEN) $405 million 1994 $1.13 billion Vaccines/oncology
Data source: company SEC filings.
Hot Financial Stocks To Own For 2023: Arc Wireless Solutions Inc.(ARCW)
ARC Wireless Solutions, Inc., together with its subsidiaries, provides wireless network components and solutions in the United States. It is involved in the design, development, manufacture, marketing, and sale of antennas and related wireless communication systems, including cellular base stations, mobiles, cellulars, and flat panel antennas. The company?s products also include global positioning systems; and conformal, portable, and other antennas, as well as antenna accessories. ARC Wireless Solutions, Inc. markets its commercial line of antennas directly to distributors, installers, and retailers of antenna accessories, as well as to commercial, government, and retail markets. It offers its products under the Freedom Antenna Exsite, Omnibase, Parity, Arc Vlpa, Airbase, and And Freedom Blade brand names. The company was formerly known as Antennas America, Inc. and changed its name to ARC Wireless Solutions, Inc. in October 2000. ARC Wireless Solutions, Inc. was founded in 1987 and is based in Denver, Colorado.
- [By Logan Wallace]
ARC Group WorldWide (NASDAQ:ARCW) issued its quarterly earnings data on Wednesday. The technology company reported ($0.12) earnings per share for the quarter, MarketWatch Earnings reports. The firm had revenue of $20.91 million during the quarter. ARC Group WorldWide had a negative return on equity of 30.03% and a negative net margin of 13.64%.
- [By Shane Hupp]
Barnes Group (NYSE: B) and ARC Group WorldWide (NASDAQ:ARCW) are both industrial products companies, but which is the superior business? We will contrast the two companies based on the strength of their earnings, risk, analyst recommendations, dividends, institutional ownership, valuation and profitability.
- [By Joseph Griffin]
News articles about ARC Group WorldWide (NASDAQ:ARCW) have been trending somewhat positive this week, according to Accern Sentiment Analysis. Accern identifies negative and positive media coverage by analyzing more than 20 million news and blog sources in real-time. Accern ranks coverage of public companies on a scale of negative one to positive one, with scores closest to one being the most favorable. ARC Group WorldWide earned a news sentiment score of 0.08 on Accern’s scale. Accern also assigned media coverage about the technology company an impact score of 45.8235732272447 out of 100, indicating that recent media coverage is somewhat unlikely to have an impact on the company’s share price in the near term.
Hot Financial Stocks To Own For 2023: West Pharmaceutical Services, Inc.(WST)
West Pharmaceutical Services, Inc. (which may be referred to as West, the Company, we, us or our) is a manufacturer of components and systems for the packaging and delivery of injectable drugs as well as components for the pharmaceutical, healthcare and consumer products industries. Our products include stoppers and seals for vials, prefillable syringe components and systems, components for intravenous and blood collection systems, safety and administration systems, advanced injection systems, and contract design and manufacturing services. Our customers include the leading global producers of pharmaceuticals, biologics, medical devices and consumer products. The Company was incorporated under the laws of the Commonwealth of Pennsylvania on July 27, 1923.
All trademarks and registered trademarks used in this report are the property of West Pharmaceutical Services, Inc., either directly or indirectly through its subsidiaries unless noted otherwise. Advisors’ Opinion:
- [By Ethan Ryder]
Get a free copy of the Zacks research report on West Pharmaceutical Services (WST)
For more information about research offerings from Zacks Investment Research, visit Zacks.com
- [By Ethan Ryder]
Northern Trust Corp reduced its stake in shares of West Pharmaceutical Services Inc. (NYSE:WST) by 0.8% in the 2nd quarter, according to the company in its most recent 13F filing with the Securities and Exchange Commission (SEC). The institutional investor owned 596,640 shares of the medical instruments supplier’s stock after selling 4,713 shares during the period. Northern Trust Corp owned about 0.81% of West Pharmaceutical Services worth $59,240,000 at the end of the most recent quarter.